Get the Daily Brief
Latest Biotech News
Krystal posts early proof-of-concept for cystic fibrosis gene therapy
Krystal reported early proof‑of‑concept clinical signals for its cystic fibrosis gene therapy program, according to a BioCentury clinical report summarizing recent trial updates. The company’s...
Illumina hires Eric Green as CMO — clinical genomics push begins
Illumina announced that Eric Green, former director of the U.S. National Human Genome Research Institute, will join as chief medical officer next month, filling a role vacant since 2023. In an...
FDA greenlights seven NMEs in December — 2025 approvals slip to 46
The FDA approved seven new molecular entities in December, bringing the agency’s 2025 total to 46 NMEs — down from 50 in 2024, BioCentury reported. The December approvals spanned multiple...
Biotech cash sprint: $4.9B raised ahead of JP Morgan
Biotech companies — private and public — pulled in roughly $4.9 billion in financing in the run‑up to the JP Morgan Healthcare Conference, with private biotechs raising at least $2.29 billion...
Mirador raises $250M — Plans IPO push
Mirador Therapeutics closed a $250 million Series B and told Endpoints News it is weighing an initial public offering later this year. The financing backs Mirador’s precision-immunology pipeline...
Boltz launches PBC to democratize AI drug design
Boltz PBC launched with a $28 million seed round led by Amplify, a16z and Zetta to commercialize open-source AI models for molecular design. Founders from MIT’s CSAIL positioned Boltz as a...
Orca secures $250M to launch T-cell therapy commercially
Orca Bio raised $250 million to support the commercial launch of its cell therapy for complications following allogeneic stem cell transplants. The financing is explicitly sized to fund launch...
Eikon files for IPO — Tests biotech rally
Eikon Therapeutics filed for a U.S. initial public offering, a move framed in coverage as a bellwether for whether renewed biotech optimism can support listings. Company filings position Eikon — a...
Aktis prices IPO — Stock pops on debut
Radiopharma developer Aktis Oncology priced an upsized IPO at $18 a share, raising $318 million in gross proceeds, and saw its stock surge about 25% in the debut trading session. The combination...
Biotech fundraising surge ahead of JPM — Billions flow
Private and public biotech firms pulled in a wave of capital in early January ahead of the JP Morgan conference. Endpoints News tallied roughly $4.9 billion in financings across private and public...
BIO launches Investment Council to boost VC access
The Biotechnology Innovation Organization launched the BIO Investment Council to connect venture investors with small and emerging biotech firms and advise on policy that affects capital...
Illumina names Eric Green as chief medical officer
Illumina appointed former NHGRI director Eric Green as chief medical officer, with Green set to join the company next month. In a Q&A, Green described plans to advocate for integrating genomics...
Krystal reports early proof-of-concept for CF gene therapy
Krystal Biotech disclosed an early proof-of-concept clinical report for its cystic fibrosis gene therapy program, according to BioCentury’s clinical updates. Early clinical observations suggested...
Phanes posts positive Phase 2 PDAC data at ASCO GI
Phanes Therapeutics announced positive Phase 2 results for spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, presented at ASCO GI 2026. Data showed activity in combination with...
Biotech cash flood: $4.9B pours into private and public companies ahead of JPM
Biotech companies drew an estimated $4.9 billion in fresh capital during the first full week of January, according to Endpoints News and other market tallies. The inflows included multiple...
Aktis pop: Radiopharma IPO raises $318M and fuels hopes for biotech listings
Radiopharmaceutical developer Aktis Oncology priced its IPO at $18 per share, raising roughly $318 million and sending shares sharply higher at debut. The upsized offering and positive market...
Big rounds fuel therapy launches: Mirador and Orca secure $250M each
Two private biotechs announced large financing rounds: Mirador Therapeutics raised $250 million in a Series B to expand its precision immunology pipeline and signaled IPO plans, while Orca Bio...
Krystal pushes mutation‑agnostic CF gene therapy: early PoC claims and fast path plan
Krystal Biotech disclosed early clinical data suggesting its mutation-agnostic approach can deliver native protein to cystic fibrosis patients and signaled plans to move directly into a pivotal...
Illumina taps former NHGRI chief: Eric Green named chief medical officer
Illumina appointed former NHGRI director Eric Green as chief medical officer, a hire the company said will accelerate its push into clinical genomics and precision medicine. Interviews and...
Open tools and AI platforms: Boltz launches with $28M; FRAIL advances molecular design
MIT spinout Boltz launched as a public-benefit company with a $28 million seed round to deliver open AI platforms for drug discovery, claiming AlphaFold‑level complex prediction and agents for...